First prostate biopsy vs rebiopsy: Analysis of our series.

Prostate re-biopsydoes not guarantee detection of prostate cancer(PC), sometimes leading to overdiagnosis of clinicallyinsignificant tumors. The present study shows theincidence of PC in our hospital and analyzes thedistribution of risk groups and prognosis depending inthe diagnosis obtained by firs...

Full description

Saved in:
Bibliographic Details
Published inArchivos españoles de urología Vol. 71; no. 10; p. 825
Main Authors Aranda-Lozano, Jorge, Sierra-Labarta, Rocio, de Pablo-Cárdenas, Álvaro, Sánchez-Zalabardo, Daniel
Format Journal Article
LanguageSpanish
Published Spain 01.12.2018
Subjects
Biopsy
Humans
Male
Neoplasm Grading
Prostate-Specific Antigen
Prostatic Neoplasms - diagnosis
Cáncer prostático
Biopsia prostática
Prostate biopsy
Risk groups
Prostate cancer
Grupos de Riesgo
Online AccessGet more information

Cover

More Information
Summary:Prostate re-biopsydoes not guarantee detection of prostate cancer(PC), sometimes leading to overdiagnosis of clinicallyinsignificant tumors. The present study shows theincidence of PC in our hospital and analyzes thedistribution of risk groups and prognosis depending inthe diagnosis obtained by first biopsy vs rebiopsy. 1. To know the incidence of ProstateCancer (PC) in patients biopsied in our hospital duringthe years 2014, 2015 and 2016 as well as thedistribution by risk and prognosis groups.2. To know if there are significant differences in thedistribution of risk and prognostic groups among patientsdiagnosed of PC by first biopsy vs rebiopsies in ourhospital in the years 2014, 2015 and 2016. A longitudinal retrospectivedescriptive and analytical study was performed with496 patients undergoing prostate biopsy (PB) in ourhospital between January 1st 2014 and December31st 2016. We analyze the results of prostate biopsy,Gleason score and distribution by prognosis group toverify if there were significant differences between firstbiopsy vs prostate biopsy. The rate of positive PB in first biopsy was38.3% compared to 26.8% in rebiopsy. There weresignificant differences (p=0.01). In our series wediagnosed in first biopsy 71.8% of significant PC andthe 90% of the of bad or very bad prognosis PC (groups4 and 5 according to the ISUP classification). There are significant differences inthe diagnosis of prostate cancer between a first biopsyand a rebiopsy. Tumors diagnosed by rebiopsies havea better prognosis than those diagnosed by first biopsy.We must adopt mechanisms to increase the diagnosticyield of re-biopsies.
ISSN:0004-0614